Drug Profile
Sabizabulin - Veru Healthcare
Alternative Names: APP-111; Bisindole; VERU-111Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Ohio State University; University of Tennessee Research Foundation
- Developer University of Tennessee Research Foundation; Veru Healthcare
- Class Anti-inflammatories; Antineoplastics; Antivirals; Imidazoles; Indoles; Ketones; Phenyl ethers; Small molecules
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration COVID 2019 infections
- Phase III Ebola virus infections; Prostate cancer; Smallpox
- Phase II SARS-CoV-2 acute respiratory disease
- Preclinical HER2 positive breast cancer
- Suspended Influenza A virus H1N1 subtype
- No development reported Solid tumours
Most Recent Events
- 07 Feb 2024 Suspended - Phase-II for Influenza A virus H1N1 subtype (PO) due to lack of funding
- 25 Jan 2024 Sabizabulin - Veru Healthcare is available for licensing as of 25 Jan 2024. https://verupharma.com/pipeline/
- 26 Sep 2023 FDA approves phase III clinical trial study to evaluate sabizabulin 9mg for the broader treatment of hospitalized adult patients who have any type of viral ARDS